Immix Biopharma (IMMX) Fundamental Analysis: Revenue, Earnings & Valuation

3.31 / 10

Netural

IMMX's fundamental quality is moderate (3.3/10). Key positives include a healthy inventory turnover ratio of 47.88 and an interest coverage ratio of 15.51, indicating solid liquidity and debt servicing ability. However, a concerning net profit to total profit ratio of 100.14 and a negative asset-to-market value of -0.51 point to inefficiencies in profitability and asset utilization. Revenue growth is robust at 78.62% YoY, but this is offset by mixed signals in other profitability metrics, leading to a neutral overall fundamental rating.

Analysis Checks(8/10)

Revenue-MV

Value-0.26

Score3/3

Weight25.10%

1M Return11.03%

Total operating revenue (YoY growth rate %)

Value78.62

Score3/3

Weight1.62%

1M Return0.88%

Inventory turnover ratio

Value47.88

Score2/3

Weight-2.09%

1M Return-1.23%

Profit-MV

Value0.47

Score2/3

Weight20.14%

1M Return8.99%

PB-ROE

Value1.82

Score2/3

Weight26.97%

1M Return10.90%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.51

Score2/3

Weight-2.17%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value92.79

Score2/3

Weight0.18%

1M Return0.10%

Asset-MV

Value-0.51

Score0/3

Weight13.61%

1M Return6.58%

Net profit / Total profit (%)

Value100.14

Score1/3

Weight-2.70%

1M Return-1.59%

Cash-MV

Value-0.07

Score2/3

Weight19.34%

1M Return8.80%

Is IMMX undervalued or overvalued?

IMMX scores 3.31/10 on fundamentals and holds a Fair valuation at present. Backed by its -174.29% ROE, 0.00% net margin, -13.75 P/E ratio, 39.21 P/B ratio, and 8.33% earnings growth, these metrics solidify its Netural investment rating.